Literature DB >> 14707290

Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway.

Rebecca L Pratt1, Michael S Kinch.   

Abstract

The EphA2 receptor tyrosine kinase is overexpressed in aggressive cancer cells, where it critically influences many aspects of malignant character. Although high levels of EphA2 have been documented in many different cancers, relatively little is known of the mechanisms that govern EphA2 gene expression in normal or malignant cells. Our present studies demonstrate that EphA2 influences the regulation of its own gene expression. Specifically, ligand-mediated phosphorylation of EphA2 transmits signals to the nucleus via extracellular signal-regulated kinase kinases to up-regulate de novo EphA2 gene expression and synthesis. This mechanism governs EphA2 expression in normal and malignant cells. In normal cells, EphA2 protein expression is balanced by ligand-mediated induction of EphA2 gene expression countered by EphA2 protein turnover. These findings suggest that EphA2 expression and ligand binding are intimately linked in epithelial cells. Increased understanding of this mechanism could have important implications for understanding the causes of EphA2 overexpression and for developing new strategies for therapeutic intervention in the many cancers that overexpress EphA2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14707290

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  7 in total

1.  The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1).

Authors:  Bénédicte Foveau; Gaylor Boulay; Sébastien Pinte; Capucine Van Rechem; Brian R Rood; Dominique Leprince
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

Review 2.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

Authors:  Manish Tandon; Sai Vikram Vemula; Suresh K Mittal
Journal:  Expert Opin Ther Targets       Date:  2011-01       Impact factor: 6.902

3.  PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.

Authors:  Orit Jacobson; Qing Li; Haojun Chen; Gang Niu; Dale O Kiesewetter; Lan Xu; Kimberly Cook; Gengcheng Yang; William Dall'Acqua; Ping Tsui; Li Peng; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2017-05-25       Impact factor: 10.057

Review 4.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

5.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Authors:  Dana M Brantley-Sieders; Guanglei Zhuang; Donna Hicks; Wei Bin Fang; Yoonha Hwang; Justin M M Cates; Karen Coffman; Dowdy Jackson; Elizabeth Bruckheimer; Rebecca S Muraoka-Cook; Jin Chen
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

6.  Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.

Authors:  Hiroya Taniguchi; Yuji Baba; Yoji Sagiya; Masamitsu Gotou; Kazuhide Nakamura; Hiroshi Sawada; Kazunori Yamanaka; Yukiko Sakakibara; Ikuo Mori; Yukiko Hikichi; Junpei Soeda; Hideo Baba
Journal:  Neoplasia       Date:  2018-05-23       Impact factor: 5.715

Review 7.  Hyaluronan and the Fascial Frontier.

Authors:  Rebecca L Pratt
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.